Evidence map›Paper›PMID 42379755›Full record

ArticleIn vivo (Athens, Greece)

Association of Pre-treatment CALLY Index With Pathological Response to Neoadjuvant Chemotherapy in Rectal Cancer.

Yasuki Akiyama, Yusuke Sawatsubashi, Kei Yabuki, Hiroto Sannomiya, Kensuke Nitta, Atsuhiro Koga, Yasuhisa Mori, Masumi Yamauchi, Jun Nagata, Nagahiro Sato and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yasuki AkiyamaDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan; y-akky-asu@med.uoeh-u.ac.jp.
Yusuke SawatsubashiDepartment of Surgery, Kurate Hospital, Kurate, Japan.
Kei YabukiDepartment of Digestive and General Surgery, Wakamatsu Hospital, University of Occupational and Environmental Health, Kitakyushu, Japan.
Hiroto SannomiyaDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kensuke NittaDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.
Atsuhiro KogaDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.
Yasuhisa MoriDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.
Masumi YamauchiDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.
Jun NagataDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.
Nagahiro SatoDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.
Toshihisa TamuraDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kazunori ShibaoDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.
Keiji HirataDepartment of Surgery 1, University of Occupational and Environmental Health, Kitakyushu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimNeoadjuvant chemotherapy (NAC) without radiotherapy is performed in selected patients with locally advanced rectal cancer (LARC); however, reliable predictors of pathological response remain unclear. This study aimed to explore the association between systemic inflammatory markers, particularly the C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index, and pathological response to NAC. PATIENTS AND

methodsFifty-nine patients with clinical stage II-III rectal cancer treated with NAC followed by surgery between 2018 and 2026 were retrospectively analyzed. Pathological response was evaluated according to the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma (ninth edition) and categorized into non-responders (grade 0-1) and responders (Grade 2-3). Pre-treatment CRP, CRP-to-albumin ratio (CAR), and CALLY index were assessed. Univariate logistic regression and receiver operating characteristic (ROC) analyses were performed.

resultsTwenty-four patients (40.7%) achieved grade 2-3 response. The number of NAC cycles was significantly higher for responders than for non-responders (

conclusionPre-treatment inflammatory markers, including the CALLY index, may help predict pathological response to NAC in locally advanced rectal cancer.

Indexed as

C-Reactive ProteinLymphocytesNeoadjuvant TherapyRectal NeoplasmsAdultAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesROC CurveTreatment OutcomeBiomarkers, TumorC-Reactive ProteinCALLY indexLocally advanced rectal cancerneoadjuvant chemotherapypathological responsesystemic inflammatory markers

Identifiers

PMID42379755
PMCPMC13322086

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.